CCND1 Antibody

1. LINC01296 is an oncogenic lncRNA in osteosarcoma. The proliferation, invasion and migration of osteosarcoma cells could be effectively retarded by inhibition of LINC01296. The cancerpromoting effect of LINC01296 on osteosarcoma was determined by cyclin D1. PMID: 30226542
2. autophagic degradation machinery and cyclin D1 linked to hepatocellular carcinoma tumorigenesis PMID: 29328502
3. FOXD2-AS1 could promote the growth of chondrocytes by targeting miR-206/CCND1 axis. PMID: 30119190
4. CCND1 , C-MYC , and FGFR1 amplifications were observed in 34.28%, 28.57%, and 17.14% of the 35 samples (invasive ductal breast carcinoma). PMID: 30119151
5. High CCND1 expression is associated with lung adenocarcinoma. PMID: 30066899
6. Down-regulation of Apaf-1 protein and the overexpression of Cyclin D1 and AQP-5 proteins possibly contribute to an aggressive serous ovarian carcinoma with a high risk of recurrence and poor response to the first-line chemotherapy. PMID: 30072015
7. Results provide evidence that Cyclin D1 is a mediator for WDR5-induced proliferation and cell cycle change in gastric neoplasm. PMID: 29125890
8. CNV analysis disclosed that plasma CCND1/CDKN2A ratio is correlated with EBV DNA load in NPC patients' plasma and could serve as a screening test to select potential CDK4/6 inhibitor treatment candidates. Based on our NPC PDX model and RNA sequencing, Palbociclib, a cyclin-dependent kinase inhibitor, proved to have anti-tumor effects by inducing G1 arrest. PMID: 30236142
9. Cyclin D1b markedly amplified integrin alphavbeta3 expression, which was further up-regulated under lipopolysaccharide stimulation. PMID: 30074214
10. This meta-analysis suggested that CCND1 rs9344 polymorphism might be associated with the risk of HCC among Caucasians. PMID: 29970717
11. Results show that CCND1 expression is regulated by LET7A which directly targets its 3'UTR in A549 lung cancer cells. PMID: 30201337
12. s found that the phenotypic alterations by miR-365 were partially due to downregulation of CCND1 and BCL2 oncogenes. PMID: 29858490
13. USP22 and CCND1 levels correlate in patient lung and colorectal cancer samples and our preclinical studies indicate that targeting USP22 in combination with CDK inhibitors may offer an approach for treating cancer patients whose tumors exhibit elevated CCND1. PMID: 30224477
14. miR449a5p may control squamous cell carcinoma proliferation through the negative regulation of cyclin D1 expression. PMID: 29845226
15. Findings demonstrated that Cyclin D1 is overexpressed in hepatocellular carcinoma cells (HCC) and that its silencing can suppress cell proliferation and promote cell apoptosis of HCC. PMID: 28885717
16. uc.338 could promote proliferation and cell cycle G1/S transition, and might target p21 downregulation and cyclin D1 upregulation. PMID: 29901203
17. overexpressed PKM2 led to increased CCND1 and decreased CDKN1A expression, whereas underexpressed PKM2 led to decreased CCND1 and increased CDKN1A expression in ovarian cancer cells. PMID: 29752805
18. CCND1 G870A polymorphism may increase the risk of lung cancer in smokers from North India, and it may be associated with the overall survival of small-cell lung cancer patients PMID: 30086699
19. these results define a tumor-supportive role for CDCA3. PMID: 29627567
20. High CCND1 expression is associated with breast cancer. PMID: 29047106
21. The novel EGR1-CCND1 axis contributes to the G1 phase arrest and cell proliferation in glioma PMID: 29246166
22. the focal adhesion component paxillin is a cytoplasmic substrate of Ccnd1.Cdk4. PMID: 27181366
23. in oral tumor cells, overexpression of cyclin D1 occurs through the activation of STAT3 and the deregulation of degradation pathway of cyclin D1 which may favors maintaining its accumulated level in cells. It also demonstrated that cyclin D1 expression can be controlled by targeting the STAT3 with its siRNA. PMID: 29516928
24. more than 50 cyclin D1-positive cells per high-power field were detected within the proliferation centres PMID: 29254788
25. Downregulation of miR-138 increases the gene and protein expression of its potential target CCND1 in OLP mucosa which might have a pivotal role in the disease pathogenesis. PMID: 28275859
26. A possible contribution of cyclin D1 and hnRNP-K expression in the initiation and progression of urinary bladder carcinoma. PMID: 29480994
27. Un-methyaltion at -56 and -54 bp CpG in the CCND1 promoter serves as a predictor for invasive progression in arsenic-induced Bowen's disease patients. PMID: 29103775
28. PSAT1, which is overexpressed in ER-negative breast cancers, is activated by ATF4 and promotes cell cycle progression via regulation of the GSK3beta/beta-catenin/cyclin D1 pathway. PMID: 29216929
29. Positivity of p53 and cyclin D1 was not found to be predictive of survival in patients with esophageal SCC which might be due to the small sample size of the present survey. PMID: 27975182
30. Studied effects of Taxillus yadoriki and Neolitsea sericea extracts on cell proliferation of cancer cells through cyclin D1 proteasomal degradation. PMID: 29925351
31. Findings indicate the substrate specificity of the F-box protein FBXO31 and the mechanism of FBXO31-regulated cyclin D1 protein turnover. PMID: 29279382
32. The s report a previously unknown long noncoding RNA which, together with CNBP, is involved in the fine-tuned regulation of CCND1 mRNA stability, without which CCND1 exhibits, at most, partial expression. PMID: 29199958
33. According to immunohistochemistry and immunoblot analysis, the expression levels of cyclin D1, cyclin E, pRb, and Ki67 in psoriasis lesions decreased after treatment and were similar with those in the normal group PMID: 29115643
34. Further study revealed AP000439.3 can regulate expression of CCND1 through enhancing estrogen receptor induction of CCND1. This finding revealed lncRNAs may serve as important effectors of ER in regulation of gene expression and cell phenotype in breast cancer PMID: 29048636
35. miR-720 acted as a tumour suppressor in pancreatic cancer by directly targeting CCND1. PMID: 28990111
36. Results identified NKX2-1-binding motifs in the cyclin D1 promoter and indicate that NKX2-1 directly and positively regulates transcription of cyclin D1 in lung adenocarcinoma. PMID: 28634225
37. Results suggest that dysregulation and activation of the cell cycle proteins CDK4/CDK6-CCND1-phospho-RB1 axis is associated with higher proliferative index in neuroendocrine tumors (NETs). PMID: 28991877
38. Results indicated that miR-193a-3p suppressed gastric growth and motility, at least partly, by directly targeting cyclin D1 (CCND1) and ETS proto-oncogene 1 (ETS1) expression. PMID: 29848678
39. Greater frequency of cyclin D1 expression was revealed in normal endometrial tissues in comparison with carcinomas. The distribution pattern of cyclin D1 immunoexpression suggests poor prognoses in endometrial carcinoma patients. PMID: 28965628
40. High Expression of CCND1 is associated with liver cancer. PMID: 28415588
41. Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas. PMID: 29489901
42. These findings indicate that miRNA494 and its target cyclin D1 may be a crucial axis for Nerve growth factor in regulating the proliferation of human corneal epithelial cell. PMID: 28765880
43. INSR rs1051690 SNP is associated with increased risk of gastric cancer, while polymorphisms in IL12B, CCND1 and IL10 genes are not linked with the presence of gastric cancer PMID: 28596683
44. s showed that CCND1 is a direct target of miR-93, and the dysregulation of the miR-93/CCND1 signaling pathway is responsible for the development of ventricular remodeling. PMID: 28817550
45. PD-L1 protein abundance is regulated by cyclin D-CDK4 and the cullin 3-SPOP E3 ligase via proteasome-mediated degradation PMID: 29160310
46. We conclude that EMSY and CCND1 work in collaboration and contribute to the pathogenesis of lung cancer. PMID: 28824300
47. Transfection of cells with ClC-3 siRNA decreased the expression of cyclin D1, cyclin dependent kinase 4 and 6, and increased the expression of cyclin dependent kinase inhibitors (CDKIs), p21 and p27. Pretreatments of cells with p21 and p27 siRNAs depleted the inhibitory effects of ClC-3 siRNA on the expression of CDK4 and CDK6, but not on that of cyclin D1 PMID: 27451945
48. HPV infection was significantly associated with amplification of both EGFR (76.5%) and cyclin D1 (73.0%). PMID: 28741068
49. our data demonstrated for the first time that inhibition of RAD51 suppressed the cervical cancer cell proliferation and the growth of cervical cancer xenografts by attenuating cell cycle transition, which could be a functional link between RAD51 and cyclin D1 and p21 PMID: 28627709
50. REVIEW: addresses the implication of SOX11 overexpression and frequent genetic lesions, cooperating with cyclin D1 underlying the pathogenesis of mantle cell lymphoma PMID: 28466437

显示更多

收起更多

HGNC: 1582

OMIM: 168461

KEGG: hsa:595

STRING: 9606.ENSP00000227507

UniGene: Hs.523852